1	Evaluation of a rapid lateral flow assay for the detection of taeniosis
2	and cysticercosis at district hospital level in Tanzania:
3	A prospective multicentre diagnostic accuracy study
4	
5	Inge Van Damme <sup>1,2¶</sup> , Chiara Trevisan <sup>1,3¶</sup> , Mwemezi Kabululu <sup>4</sup> , Dominik Stelzle <sup>5</sup> , Charles E.
6	Makasi <sup>6,7</sup> , Veronika Schmidt-Urbaneja <sup>5</sup> , Kabemba E. Mwape <sup>8</sup> , Chishimba Mubanga <sup>9</sup> , Gideon
7	Zulu <sup>8,10</sup> , Karen S. Møller <sup>11</sup> , Famke Jansen <sup>12</sup> , Dries Reynders <sup>13</sup> , John Noh <sup>14</sup> , Sukwan
8	Handali <sup>14</sup> , Emmanuel Bottieau <sup>15</sup> , Andrea S. Winkler <sup>5,16,17</sup> , Pierre Dorny <sup>12</sup> , Pascal
9	Magnussen <sup>18</sup> , Sarah Gabriël <sup>1&amp;*</sup> , Bernard Ngowi <sup>6,19&amp;</sup>
10	
11	<sup>1</sup> Department of Translational Physiology, Infectiology and Public Health, Faculty of
12	Veterinary Medicine, Ghent University, Merelbeke, Belgium
13	<sup>2</sup> Service Foodborne Pathogens, Sciensano, Brussels, Belgium
14	<sup>3</sup> Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium;
15	<sup>4</sup> Tanzania Livestock Research Institute (TALIRI), Central Zone Office, Mpwapwa, Dodoma,
16	Tanzania
17	<sup>5</sup> Department of Neurology, Center for Global Health, Technical University of Munich,
18	Germany
19	<sup>6</sup> National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es
20	Salaam, Tanzania
21	<sup>7</sup> Kilimanjaro Christian Medical University College, Moshi, Tanzania
22	<sup>8</sup> Department of Clinical studies, School of Veterinary Medicine, University of Zambia,
23	Lusaka, Zambia

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1

- <sup>9</sup> Chishimba Mubanga: Ministry of Agriculture, Shibuyunji, Government of the Republic of
- 25 Zambia
- <sup>10</sup> Gideon Zulu: Ministry of Health, Government of the Republic of Zambia.
- 27 <sup>11</sup> Danish Food and Veterinary Administration, Denmark
- <sup>28</sup> <sup>12</sup> Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
- <sup>13</sup> Department of Applied Mathematics, Computer Science and Statistics, Ghent University
- 30 <sup>14</sup> Parasitic Diseases Branch, Division of Parasitic Diseases, Center for Global Health,
- 31 Centers for Disease Control and Prevention, USA
- 32 <sup>15</sup> Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
- <sup>16</sup> Department of Community Medicine and Global Health, Institute of Health and Society,
- 34 University of Oslo, Norway
- <sup>17</sup> Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA,
- 36 USA
- <sup>18</sup> Pascal Magnussen: Department of Immunology and Microbiology, Faculty of Health and
- 38 Medical Sciences, University of Copenhagen, Denmark
- <sup>19</sup> University of Dar es Salaam, Mbeya College of Health and Allied Sciences, Mbeya
- 40 Tanzania
- 41 \* Corresponding author: <u>sarah.gabriel@ugent.be</u>
- 42 ¶ These authors contributed equally to this work.
- 43 & These authors also contributed equally to this work
- 44
- 45 **Short title**: TS POC for taeniosis and cysticercosis

#### 46 Abstract

The TS POC test, *Taenia solium* point-of-care test, is a two-strip lateral flow assay using the 47 48 recombinant antigen rES33 on the TS POC T test strip, and rT24H on the TS POC CC test 49 strip, to detect antibodies against T. solium taeniosis and cysticercosis, respectively. 50 The objective of this study was to assess the diagnostic performance of the TS POC test for 51 the detection of *T. solium* taeniosis and cysticercosis in individuals attending district hospitals 52 in Tanzania. 53 In this prospective two-phase diagnostic accuracy study, we recruited participants aged 10 and above, excluding pregnant women and those with acute severe illness. Participants were 54 55 consecutively recruited in three cohorts according to their signs/symptoms: compatible with 56 neurocysticercosis (cohort 1), intestinal worm infections (cohort 2), and other symptoms 57 (cohort 3). Lacking a gold standard test for both infections, evaluating the diagnostic 58 accuracy measures was done using the results of different coprological and serological tests 59 in a Bayesian Latent Class Model approach. 60 The TS POC test was conducted on 601 participants in cohort 1, 1661 participants in cohort 61 2, and 662 participants in cohort 3. Most individuals tested negative on both TS POC test 62 strips, with proportions of 83% (n = 496), 97% (n = 1613) and 97% (n = 641) in cohorts 1, 2 63 and 3, respectively. Sensitivity values for the TS POC T test strip were 50.2% [4.9 - 96.4], 40.8% [2.2 - 95.2], and 40.4% [2.3 - 95.0], while specificity values were 98.6% [97.1 - 99.6]. 64 99.3% [98.7 - 99.7] and 99.4% [98.5 - 99.9], respectively. For the TS POC CC test strip, the 65 sensitivity was 77.5% [37.8 - 99.2], 24.9% [95% CI 6.4 - 52.7] and 44.2% [6.6 - 91.5], and 66 the specificity 92.3% [86.5 - 98.8], 99.1% [97.8 - 100], and 98.1% [96.1 - 99.7] across the 67 68 respective cohorts. Although the TS POC test has a suboptimal sensitivity, it demonstrates a high specificity. 69

70 which may have clinical utility to guide treatment and diagnostic decisions, or in

epidemiological studies. An important strength of this study lies in its assessment of the TS
POC test under real-world conditions, revealing divergent estimates across distinct cohorts.
The study underscores the suboptimal performance of existing tests under field conditions,
emphasizing the need for the development and validation of better diagnostic tests. **Keywords**: lateral flow assay; *Taenia solium*; resource-poor settings; rapid diagnostic test;
point of care

77 Registration number: PACTR201712002788898

## 78 Author summary

79 Taenia solium poses significant public health concerns globally and is a leading cause of 80 acquired epilepsy in T. solium endemic areas. The parasite causes two distinct infections in 81 humans: taeniosis, an intestinal infection, and cysticercosis, a tissue infection. The disease is 82 particularly prevalent in low-resource settings, contributing to substantial morbidity and 83 economic burdens. Recently, a test was specifically developed as an affordable and rapid 84 diagnostic tool, tailored for deployment in resource-constrained regions. The TS POC test is composed of two test strips, one to detect taeniosis and one for cysticercosis. This study 85 86 provides a critical assessment of the diagnostic efficacy of the TS POC test in Tanzanian 87 district hospital settings. By evaluating the test's performance across diverse cohorts and realworld conditions, the research sheds light on the limitations of existing diagnostic modalities 88 89 and underscores the imperative for improved testing strategies. The findings offer valuable 90 insights for public health practitioners and policymakers striving to enhance diagnostic 91 capabilities and ultimately mitigate the burden of *T. solium* infections in endemic regions.

## 92 **1** Introduction

Taenia solium is an important zoonotic parasite, affecting humans and pigs. In humans, 93 94 infections can have different presentations. The adult tapeworm resides in the intestines of 95 humans (taeniosis), while its larvae can lead to a systemic infection (cysticercosis, CC). 96 Humans become infected with the tapeworm by consuming undercooked or raw pork that 97 contains cysticerci. When eggs of the tapeworm are ingested, larvae can encyst in various tissues of the human body, including the central nervous system, causing neurocysticercosis 98 99 (NCC). The impact of *T. solium* on public health, economics, and social welfare is 100 significant, particularly in resource-limited settings. In Tanzania, the prevalence of T. solium 101 taeniosis and cysticercosis is high [1,2], resulting in significant public health and economic 102 consequences [3]. 103 Diagnosis of *T. solium* taeniosis and cysticercosis in humans is currently performed through 104 laboratory-based methods targeting antigens and antibodies, such as enzyme-linked 105 immunosorbent assay (ELISA) and immunoelectrotransfer blot (EITB) assay [4,5], and also basic coprological methods for taeniosis [6]. If there is a suspicion of NCC, either on clinical 106 107 grounds and/or positive cysticercosis serology, neuroimaging such as computed tomography 108 is the diagnostic tool of choice. Also, several molecular methods are available for the 109 diagnosis of taeniosis and the confirmation of cysticercosis lesions, which are mostly PCR-110 based [4,7]. Most of these methods are time-consuming, expensive and/or not readily available in rural areas, leading to a significant challenge in the management of these 111 112 infections [8]. Rapid diagnostic tests (RDTs) have revolutionized the field of diagnostics by 113 providing fast and easy-to-use tools for the detection of diseases in resource-limited settings. 114 However, the accuracy of RDTs is often questioned, as field validation is often not performed 115 [9].

116 For taeniosis, a rapid test that can be performed at the point of care (POC) would facilitate 117 timely and targeted treatment, reducing disease transmission. Furthermore, an easy and rapid 118 test for the detection of cysticercosis may be useful in patient care, disease monitoring 119 programs and epidemiological studies. As such, an easy-to-use POC test (called TS POC test) has been developed for *T. solium* by the Centers for Disease Control and Prevention (CDC) 120 121 and the Technical University of Munich (TUM). The test showed a promising sensitivity and 122 specificity to detect T. solium taeniosis and NCC during its preliminary evaluation under 123 laboratory conditions. To evaluate its real-world performance in resource-poor, highly 124 endemic areas in sub-Saharan Africa, the performance characteristics of the TS POC test were evaluated in two different settings: in rural communities in Zambia [10], and in district 125 126 hospitals in Tanzania [11]. The evaluation of the TS POC test for the detection of T. solium 127 taeniosis and cysticercosis at community level has been reported elsewhere [12,13]. Also the 128 evaluation of the TS POC test for the neuroimaging-based diagnosis of NCC in both settings 129 were reported elsewhere [14,15], and are thus out of the scope of this paper. The focus of this 130 paper is the evaluation of the TS POC test for the detection of infection with the adult tapeworm (taeniosis) and/or the larval stage (cysticercosis) of T. solium in individuals 131 132 attending district hospitals (Tier 2 level) in Tanzania. The primary endpoints of this paper are the sensitivity and specificity of the TS POC test for the detection of both infections, 133 134 evaluated in three different clinical cohorts.

# 135 2 Material and methods

136 The trial was registered at the Pan African Clinical Trials Registry with identifier

137 PACTR201712002788898. A comprehensive description of the trial rationale, design and

138 methodology can be found in Trevisan et al. [11]. Only the methodological details relevant

139 for this manuscript are summarized in this paper, i.e. only focusing on *T. solium* taeniosis and

cysticercosis testing. The evaluation of the TS POC CC test strip for NCC diagnosis isdescribed elsewhere [14,15].

#### 142 **2.1 Study design**

143 The study was designed as a prospective, two-phase, multicentre diagnostic accuracy study. 144 First, all participants were tested using the TS POC test (phase 1), after which all participants 145 testing positive and a subset of the participants testing negative were requested to provide a 146 blood and stool sample for further reference testing (phase 2). Since there is no gold standard as comparison method for neither of the infections, the performance of the TS POC test was 147 148 assessed using a combination of reference tests. The details of these tests can be found in 149 section 2.4, sample collection and reference testing. The TS POC test is a two-strip lateral 150 flow assay prototype. The primary aim of this paper is to determine the sensitivity and 151 specificity of the TS POC T test strip and TS POC CC test strip for the detection of T. solium 152 taeniosis and cysticercosis, respectively, in individuals attending district hospitals in 153 Tanzania. As sensitivity and specificity are known to differ between study populations, the 154 evaluation was done in three different cohorts: 1) individuals with specific neurological signs and symptoms compatible with NCC (epilepsy and/or severe progressive headache) (from 155 156 now on referred to as « cohort 1 »); 2) individuals with complaints compatible with intestinal 157 worm infections such as abdominal pain and loss of appetite (cohort 2); and 3) individuals with other symptom(s), such as coughing, limb pain, hypertension, and diabetes patients 158 (cohort 3). 159

## 160 2.2 Participants

Participants were enrolled between December 2017 and February 2020 in three district
hospitals in southern Tanzania: Mbeya (rural) District (Ifisi) and Rungwe District (Tukuyu),
both located in Mbeya Region, and Mbozi District (Vwawa), located in Songwe Region. To

be included, individuals aged 10 years or above had to be willing and able to provide written informed consent, living in the study area for the past three months and planning to stay in the same area throughout the study period. Pregnant women and individuals with acute severe illness that needed in-patient care were excluded. Different additional criteria were used to be included in the different cohorts.

169 Individuals with signs/symptoms compatible with NCC (cohort 1) were consecutively

170 recruited from Outpatient Departments (OPD) and the Mental Health Clinics (MHC). A

171 questionnaire consisting of nine questions was used to assess if individuals fulfilled the

172 criteria for epileptic seizures and/or severe progressive headache (S1 Appendix; more details

173 can be found in Stelzle et al. [14,16]). For cohort 2, individuals who presented at the OPD

174 with complaints compatible with intestinal worm infection were included. They needed to

175 have at least one of the following signs/symptoms: abdominal pain/discomfort, having seen

176 worm parts in the stool, express having a worm in the stomach, nausea, diarrhoea and loss of

appetite. All other people presenting at the OPD, without signs/symptoms compatible with

178 cohort 1 or cohort 2, were potential candidates to be included in cohort 3. Participants with

epilepsy and/or headache (cohort 1) or symptoms compatible with intestinal worm infections

180 (cohort 2) were consecutively recruited. For cohort 3, every 10<sup>th</sup> individual was approached

181 for enrolment in the study.

182 Eligible participants were informed about the study and were invited to provide informed

183 consent. Written informed consent (assent for minors, with written consent of

184 parent/guardian) was obtained from all participants. Following consent, demographic and

185 clinical data were collected from participants, including self-reported age, and gender.

186 **2.3 TS POC test** 

187 The TS POC is an antibody-detecting lateral flow assay, using two test strips, each with a 188 previously characterised recombinant protein, rES33 for the TS POC T test strip and rT24H 189 for the TS POC CC test strip [17,18]. During initial assessments conducted within laboratory 190 settings using known positive and negative control sera, the TS POC test demonstrated 191 encouraging results. The TS POC T test strip exhibited a sensitivity of 82% and a specificity 192 of 99% in detecting taeniosis. In the case of NCC, the TS POC CC test strip had a sensitivity 193 of 88%, and 93% for infection with multiple cysticerci, with a corresponding specificity of 194 99%. The TS POC cassette prototype was assembled at CDC, Atlanta. 195 Details about the TS POC test and testing procedures have been described elsewhere 196 [10,12,13,19]. In short, 20 µL blood was collected from a fingertip and placed in a sample 197 port of one of the test strips, and the same procedure was repeated for the other test strip. 198 After applying chase buffer, the TS POC test was read after 20 minutes. A TS POC test strip 199 was considered positive when the control line and test line were positive (visible as a red 200 line). The result was invalid when the control line was negative. The result was negative 201 when the control line was positive and test line negative. The results were read by two 202 different readers. When there was disagreement between the readers, the result of a third 203 reader was decisive.

### 204 **2.4** Sample collection and reference testing

Participants testing positive for one or both TS POC test strips, and every 10<sup>th</sup> participant
testing negative on both strips, were further sampled and tested. Since there is no gold
standard test available for taeniosis nor cysticercosis, multiple imperfect tests were used as
reference tests. For taeniosis, the following three tests were used: 1) copro Ag ELISA
according to Allan et al. [20] and modified by Mwape et al. [21] to detect *Taenia* antigens in
stool using a predefined cut-off value; 2) copro mPCR according to Yamasaki et al. [7] to

211	detect Taenia DNA in stool, which was considered positive only when a 720 bp T. solium
212	band was visible; and 3) rES33-EITB to detect antibodies in serum [22], which was positive
213	when the rES33 band was visible. For cysticercosis, two serum-based tests were used: 1)
214	serum Ag ELISA to detect antigens [23] using a pre-determined protocol to determine the
215	cut-off value, and 2) rT24H-EITB to detect antibodies [17], which was considered positive
216	when the rT24H band was visible. Although also the LLGP-EITB was initially planned to be
217	included in the study [11], the results of this in-house test could not be used due to doubts
218	about the validity of the test results [13]. Further details regarding the reference tests are
219	available in the study protocols [10,11]. No adverse events were recorded.
220	Samples were shipped from Tanzania to Belgium for analysis. The PCR assays, copro Ag
221	ELISA and immunoblots were performed at the Institute of Tropical Medicine (Antwerp,
222	Belgium). Serum Ag ELISA was performed at Ghent University (Merelbeke, Belgium).
223	Samples arriving at the laboratories were only labelled with a pseudonymized code, so
224	laboratory personnel performing the tests were blinded to the TS POC result and the
225	participant's cohort.

### 226 2.5 Statistical analysis

#### 227 2.5.1 Bayesian analysis

The primary objective of this paper was to determine the sensitivity and specificity of: 1) the TS POC T test strip for the detection of taeniosis, and 2) the TS POC CC test strip for the detection of cysticercosis. Due to the lack of a gold standard test for infection with adult worm and larval stages of *T. solium*, diagnostic accuracy measures were estimated using a Bayesian Latent Class Model (BLCM)-like approach according to Berkvens et al. [24] using Open BUGS software version 3.2.3 (www.openbugs.net). The analysis allowed the

sensitivities and specificities to differ conditional on the other test results. The analyses were

- 235 performed for each of the three cohorts separately.
- 236 This study was reported following the Standards for Reporting of Diagnostic Accuracy
- studies that use BLCMs (STARD-BLCM) [25].
- 238 Sensitivity and specificity of the TS POC test were considered co-primary endpoints. The
- 239 positive/negative predictive values, the prevalence, and the accuracy measures of the
- 240 reference tests were also estimated using the models and were considered exploratory
- endpoints.
- 242 2.5.1.1 Handling missing and inconclusive results

243 The test strips of the TS POC test were read by two readers, and a third reader in case the first 244 two readers disagreed. There were no inconclusive TS POC results found. For cysticercosis, 245 participants with one or more missing blood results were excluded from the analysis, and for 246 taeniosis, participants with a missing result for a blood test and/or stool test were excluded, i.e. a complete case analysis was performed. To avoid partial verification bias due to the two-247 248 phase sampling, the multinomial probabilities in the models were adapted according to the 249 observed sampling frequencies. The weighting was determined by the proportion of complete 250 cases per test strip result.

251 2.5.1.2 Priors

For the probabilistic constraints in the Bayesian analyses, initially the same priors were used as described previously, for the evaluation of the TS POC test accuracy at community level (Mubanga, Trevisan, et al., 2021; Mubanga, Van Damme, et al., 2021). However, the priors were revised since diagnostic accuracy measures differ according to the target population, and the data did not support the priors in certain models, as demonstrated by high Bayesian P values (see S2 Appendix for all model outcomes). Therefore, new priors were defined based

on the knowledge that was obtained about the test performance during the field studies at
community level (Mubanga, Trevisan, et al., 2021; Mubanga, Van Damme, et al., 2021). The
outputs of the least restrictive models of the community-based studies were used as a basis to
determine the new sets of priors and were updated after a more thorough literature search
whenever necessary. The priors that were used during the first (initial priors) and second
(new priors) round of analyses, including the rationale, are given in S2 Appendix.

264 2.5.1.3 Models

265 Only the output of the final models is reported in the main article for clarity, but the output of all models that were performed can be found in S2 Appendix for completeness. The output of 266 267 the new sets of priors was used as the final model for most analyses. Only for the evaluation 268 of cysticercosis tests in cohort 2, the results from the model using the least restrictive original 269 priors were used because this model fitted considerably better compared to the model using 270 the new priors (Bayesian p value of 0.635 and 0.790, respectively; see S2 Appendix). 271 Due to the low number of positive cases for taeniosis, all analyses for taeniosis were repeated 272 for the three cohorts combined. When combining the three cohorts, one overall prevalence 273 (for the mixture of the three cohorts) was estimated, and the conditional sensitivities and 274 specificities were assumed to be equal. The overall models (combining the three cohorts) are 275 included in S2 Appendix, but they are not reported in the main manuscript due to the high 276 Bayesian p values, indicating a bad fit.

For the evaluation of the TS POC T strip, the TS POC CC test strip result was included in all

278 models to account for the relatively large number of TS POC CC positive participants within

TS POC T negative complete cases. Since rES33-EITB detects exposure (antibodies) whereas

280 copro mPCR and copro Ag ELISA detect infection (parasitic DNA and proteins,

respectively), the analyses were also repeated without rES33-EITB to estimate the accuracy

for detecting active infection. The estimates from models with and without rES33-EITB were

very similar (see S2 Appendix), so only the models including rES33-EITB are reported as
final model for taeniosis.

#### 285 **2.5.2** Agreement between tests

286 Cohen's kappa statistics, and positive/negative agreements were calculated to explore the

agreement between different tests [26]. The observed frequencies of the complete cases were

288 inversely weighted according to their sampling frequencies to calculate the measures of

agreement.

#### 290 2.5.3 Sample size and descriptive statistics

291 The sample sizes were calculated to obtain a desired precision of 10% around the sensitivity

and specificity of the TS POC test, resulting in 600 individuals in cohort 1, and 2000

individuals, distributed over cohort 2 and 3 [11]. Demographic characteristics of participants

were reported descriptively, using R version 4.2.3 [27].

#### 295 **2.6 Ethical clearance**

296 The study adhered to the principles outlined in the Declaration of Helsinki and obtained

297 ethical approval from the National Ethics Health Research Committee (NatREC) of Tanzania

298 (NIMR/HQ/R.8a/Vol.IX/2597), the Institute of Tropical Medicine (IRB/AB/ac/112 Ref

299 1177/17) through the ethics committee of the University of Antwerp (EC UZA 17/31/352),

300 and the Technical University of Munich via their Ethics Committee at the Klinikum rechts

301 der Isar, Munich (299/18S).

#### 302 **3 Results**

#### 303 **3.1 Study population**

- 304 In total, 3055 participants were recruited in three district hospitals in Tanzania. Participants
- 305 were recruited for neurological signs/symptoms compatible with NCC (cohort 1, n = 742);
- 306 complaints compatible with intestinal worm infection (cohort 2; n = 1661); and other
- 307 symptoms (cohort 3; n = 663). The flows for each of the three cohorts are visualised in Figs
- 308 1-3, respectively. The TS POC test was performed in 601 participants of cohort 1, 1661
- 309 participants of cohort 2, and 662 participants of cohort 3. The baseline characteristics of these
- 310 participants in each of the three cohorts are given in Table 1. The median age varied between
- 311 33 and 40 years and the proportion of women varied between 52% and 69%.

#### Table 1. Baseline characteristics of participants tested using the TS POC test, in each of the three cohorts, recruited in three district hospitals in Tanzania.

	Cohort 1	Cohort 2	Cohort 3		
	(n = 601)	(n = 1661)	(n = 662)		
Age (in years)					
Mean	36	38	43		
Median					
[interquartile	33 [23]	33 [32]	40 [28]		
range]					
Gender					
Female (%)	313 (52%)	1146 (69%)	445 (67%)		
Male (%)	288 (48%)	515 (31%)	217 (33%)		

- 314 Cohort 1: people with specific neurological signs and symptoms (epilepsy and/or severe progressive
- 315 headache); cohort 2: people with complaints compatible with intestinal worm infections; cohort 3: people 316 with any other symptom(s).



318

# Figure 1. Flow diagram of participants with specific neurological signs and symptoms compatible with NCC (cohort 1).

321 TS POC: *T. solium* point-of-care test; rT24H-EITB: recombinant T24H enzyme-linked

322 immunoelectrotransfer blot, serum Ag ELISA: enzyme-linked immunosorbent assay detecting *Taenia* 

323 antigens in serum; rES33-EITB: recombinant ES33 enzyme-linked immunoelectrotransfer blot, copro

324 mPCR: multiplex polymerase chain reaction in stool, copro Ag ELISA: enzyme-linked immunosorbent

325 assay detecting *Taenia* antigens in stool. The numbers after each of the taeniosis and cysticercosis test

326 results refer to the number of positive samples.



#### 327

#### 328 Figure 2. Flow diagram of participants with complaints compatible with intestinal worm

#### 329 infections (cohort 2).

330 TS POC: *T. solium* point-of-care test; rT24H-EITB: recombinant T24H enzyme-linked

331 immunoelectrotransfer blot, serum Ag ELISA: enzyme-linked immunosorbent assay detecting *Taenia* 

- 332 antigens in serum; rES33-EITB: recombinant ES33 enzyme-linked immunoelectrotransfer blot, copro
- 333 mPCR: multiplex polymerase chain reaction in stool, copro Ag ELISA: enzyme-linked immunosorbent
- 334 assay detecting *Taenia* antigens in stool. The numbers after each of the taeniosis and cysticercosis test
- 335 results refer to the number of positive samples.



336

# Figure 3. Flow diagram of participants attending district hospitals with symptoms other than neurological and gastro-intestinal (cohort 3).

339 TS POC: T. solium point-of-care test; rT24H-EITB: recombinant T24H enzyme-linked

340 immunoelectrotransfer blot, serum Ag ELISA: enzyme-linked immunosorbent assay detecting Taenia

antigens in serum; rES33-EITB: recombinant ES33 enzyme-linked immunoelectrotransfer blot, copro

342 mPCR: multiplex polymerase chain reaction in stool, copro Ag ELISA: enzyme-linked immunosorbent

343 assay detecting *Taenia* antigens in stool. The numbers after each of the taeniosis and cysticercosis test

344 results refer to the number of positive samples.

345

346 In cohort 1, 422 participants were recruited from the mental health clinic, and 170 from the

347 outpatient department (S1 Appendix). Based on the initial screening questionnaire

348 administered by local nurses, participants were recruited for both headache and epilepsy (n =

- 349 307), only epilepsy (n = 169) or only headache (n = 125). An overview of symptoms based
- 350 on the screening questionnaires is given in S1 Appendix. More details regarding the

351 characteristics and neurological signs/symptoms of participants in cohort 1 can be found in

#### 352 Stelzle *et al.* [16].

- 353 In cohort 2, participants were included with gastro-intestinal symptoms. Out of the
- participants with complete data for the screening questionnaire (n = 1537), most indicated to
- have three (n = 595) or two (n = 568) symptoms, and fewer had one (n = 252), four (n = 117)
- or five (n = 5) symptoms. Most participants reported abdominal pain/discomfort (n = 1438),
- followed by loss of appetite (n = 827), nausea (n = 796), diarrhoea (n = 403), express having

a worm in the stomach (n = 110) and having seen worm parts in their stool (n = 92).

#### 359 **3.2 TS POC test results**

Within the three cohorts, most participants tested negative using both TS POC test strips (n = 496, 83%; n=1613, 97%; n=641, 97% in cohort 1, 2 and 3, respectively). All participants who were positive for at least one test strip and a subset of participants negative using both test strips were selected to give a blood and stool sample for reference testing. Overall, 287 complete cases, *i.e.* results available for all reference tests, were obtained for the evaluation of taeniosis, and 303 complete cases were obtained for cysticercosis. Details regarding the TS

366 POC result combinations within each of the cohorts can be found in the respective flow

diagrams (Figs 1-3).

#### 368 3.3 Taeniosis tests

Most participants provided a stool sample immediately after recruitment, with a median duration of two days between the TS POC test and processing of the stool sample in the hospital lab (based on 220 participants for whom both dates were known). Nevertheless, 27 participants provided a stool sample more than one month after recruitment.

#### 373 **3.3.1 Reference test results**

- Table 2 shows the results of the 287 complete cases for the evaluation of *T. solium* taeniosis,
- per cohort. Within TS POC T negative participants, the majority (231/267, 87%) tested
- 376 negative using all taeniosis reference tests. Also, within TS POC T positive complete cases,
- 377 most participants (12/20, 60%) tested negative using all reference tests.

Table 2. Cross tabulation of the tests used to detect taeniosis within the three cohorts (complete cases only, n = 287).

TS POC T	rES33-	Copro	Copro Ag	Cohort 1		Cohort 2		Cohort 3		Total
test strip	EITB	mPCR	ELISA	TS	TS	TS	TS	TS	TS	
				POC CC-	POC CC+	POC CC-	POC CC+	POC CC-	POC CC+	
negative	negative	negative	negative	27	63	73	22	34	12	231
negative	negative	negative	positive	0	4	3	0	1	2	10
negative	negative	positive	positive	0	1	1	0	0	0	2
negative	positive	negative	negative	0	16	3	4	0	1	24
positive	negative	negative	negative	2	1	5	1	2	1	12
positive	negative	negative	positive	0	1	0	0	0	0	1
positive	positive	negative	negative	1	3	0	2	0	0	6
positive	positive	positive	positive	0	1	0	0	0	0	1

TS POC T: *T. solium* point-of-care test strip for taeniosis; rES33-EITB: recombinant ES33 enzyme-linked immunoelectrotransfer blot, copro mPCR: multiplex polymerase chain reaction in stool, copro Ag ELISA: enzyme-linked immunosorbent assay detecting *Taenia* antigens in stool. The numbers within each cohort represent the number of participants for each TS POC T and TS POC CC test strip result combination. A two-phase design was used, selecting only a subset of the TS POC negative population for reference testing, so particularly participants that were negative using both TS POC test strips are

underrepresented. Combinations of test results that did not occur in the dataset are not included in thetable.

#### 388 **3.3.2 Diagnostic performance measures**

- 389 The TS POC T test strip had an estimated sensitivity of 50.2% [95% CI 4.9 96.4] in cohort
- 390 1, 40.8% [2.2 95.2] in cohort 2, and 40.4% [2.3 95] in cohort 3. The specificity was 98.6%
- 391 [97.1 99.6], 99.3% [98.7 99.7] and 99.4% [98.5 99.9], respectively. The sensitivity and

- 392 specificity of the TS POC T test strip, rES33-EITB, copro Ag ELISA and copro mPCR are
- 393 visualised in Figure 4. The estimated sensitivities of all tests were low, ranging from 40.8%
- to 56.5%, and all had wide credible intervals. The prevalence of *T. solium* taeniosis in the
- 395 cohorts was estimated at 1.1% [0.1 3.5] (cohort 1), 0.3% [0 1.4] (cohort 2), and 0.5% [0 -
- 396 2.4] (cohort 3). The positive predictive values of the TS POC T test strip were 25% [0.9 -
- 397 71.6], 10% [0.2 41.2], and 20.1% [0.4 73.1], and the negative predictive values were
- 398 99.4% [97.2 100], 99.8% [98.8 100], 99.6% [97.9 100], and 99.8% [98.9 100] for the
- 399 three cohorts, respectively (S2 Appendix).



# Figure 4. Sensitivity and specificity of the TS POC T test strip, rES33-EITB, copro Ag ELISA and copro mPCR to detect taeniosis in three cohorts of participants recruited at district hospitals in

#### 403 Tanzania.

400

Results of the same cohort are indicated with the same colour. The error bars indicate the 95% credible
intervals around the mean estimates. Cohort 1: participants with specific neurological signs and
symptoms compatible with NCC (epilepsy and/or severe progressive headache); cohort 2: participants
with complaints compatible with intestinal worm infections; cohort 3: participants with other
symptom(s). TS POC T: *T. solium* point-of-care test strip for taeniosis; rES33-EITB: recombinant ES33
enzyme-linked immunoelectrotransfer blot, copro Ag ELISA: enzyme-linked immunosorbent assay
detecting *Taenia* antigens in stool, copro mPCR: multiplex polymerase chain reaction in stool.

#### 411 **3.3.3 Agreement between taeniosis tests**

- 412 The point estimates for agreement and positive agreement were low among all tests for
- 413 taeniosis (Table 3). Due to the low number of test positive samples, the estimates for
- 414 agreement should be interpreted with caution. There was no agreement between the TS POC
- 415 T test and any of the reference tests within cohort 2 and cohort 3. Also, the agreement
- 416 between rES33-EITB and the stool-based tests was low, with positive agreements from 0 to

- 417 8%. Only within cohort 1, the agreement between the TS POC T test strip and rES33-EITB
- 418 was fair, with 31% positive agreement. All three copro mPCR positive cases within this
- 419 cohort were also positive using copro Ag ELISA.

## $420 \qquad {\rm Table \ 3. \ Agreement \ between \ the \ different \ tests \ for \ taeniois is \ and \ cysticer cosis, \ for \ the \ three}$

#### 421 different cohorts of participants.

	Cohort 1	Cohort 2	Cohort 3
Taeniosis tests			
TS POC T - rES33-EITB	0.29   0.31   0.98	0.04   0.05   0.98	0.00   0.00   1.00
TS POC T – copro mPCR	0.17   0.18   0.99	-0.01   0.00   0.99	0.00   0.00   1.00
TS POC T – copro Ag ELISA	0.23   0.24   0.99	-0.01   0.00   0.97	-0.01   0.00   0.98
rES33-EITB – copro mPCR	0.07   0.08   0.98	-0.02   0.00   0.97	0.00   0.00   1.00
rES33-EITB – copro Ag ELISA	0.05   0.06   0.98	-0.04   0.00   0.95	0.00   0.00   0.98
Copro mPCR – copro Ag ELISA	0.43   0.43   1.00	0.39   0.40   0.98	0.00   0.00   0.98
Cysticercosis tests			
TS POC CC - rT24H-EITB	0.66   0.70   0.95	0.33   0.35   0.98	0.38   0.39   0.99
TS POC CC – serum Ag ELISA	0.57   0.63   0.94	0.27   0.30   0.97	0.15   0.18   0.95
rT24H-EITB – serum Ag ELISA	0.74   0.76   0.97	0.18   0.22   0.96	0.10   0.11   0.96

422 The numbers indicate Cohen's kappa, positive and negative agreement, respectively. Point estimates were 423 calculated based on complete cases, which were inversely weighted according to their observed sampling

424 frequencies (according to the TS POC C and TS POC T result combination) to account for the study design.

#### 425 3.4 Cysticercosis

#### 426 **3.4.1 Reference test results**

427 The results of cysticercosis tests for the complete cases within each of the three cohorts is

428 shown in Table 4. Within TS POC CC negative complete cases, only few were positive using

- 429 either serum Ag ELISA or rT24H-EITB, and none of the POC CC negative participants
- 430 tested positive using both reference tests simultaneously. Within TS POC CC positive

- 431 complete cases, most participants tested positive using both reference tests or negative using
- 432 both reference tests (Table 4).

TS POC	TS POC rT24H-		Cohort 1		Cohort 2		Cohort 3		Total
CC test strip	CC test EITB strip	ELISA	POC T-	POC T+	POC T-	POC T+	POC T-	POC T+	
negative	negative	negative	29	3	80	5	34	2	153
negative	negative	positive	1	0	4	0	3	0	8
negative	positive	negative	0	0	3	0	0	0	3
positive	negative	negative	36	1	13	1	9	0	60
positive	negative	positive	6	0	1	0	3	0	10
positive	positive	negative	6	0	1	0	0	1	8
positive	positive	positive	39	5	12	2	3	0	61

# Table 4. Cross tabulation of the tests used to detect cysticercosis within the three cohorts of participants (complete cases only; n = 303).

TS POC CC: *T. solium* point-of-care test strip for cysticercosis; rT24H-EITB: recombinant T24H enzymelinked immunoelectrotransfer blot, serum Ag ELISA: enzyme-linked immunosorbent assay detecting *Taenia* antigens in serum. The numbers within each cohort represent the number of participants for each
result combination. A two-phase design was used, selecting only a subset of the TS POC negative
population for reference testing, so participants that were negative on both TS POC test strips are

440 underrepresented.

#### 441 **3.4.2** Diagnostic performance of cysticercosis tests

442 The complete cases in Table 4 were used to estimate the performance characteristics of the

443 TS POC CC test strip, for each of the three cohorts separately. The sensitivity and specificity

444 of the final models are visualised in Figure 5. The sensitivity of the TS POC CC test strip was

445 77.5% [37.8 - 99.2] in cohort 1, 24.9% [6.4 - 52.7] in cohort 2, and 44.2% [2.3 - 95] in cohort

- 446 3. The specificity was 92.3% [86.5 98.8], 99.1% [97.8 100], and 98.1% [96.1 99.7],
- 447 respectively. The point estimates of the sensitivity of all tests were higher in cohort 1 than in
- the other two cohorts. The prevalence of cysticercosis was estimated at 15.3% [8.1 29.4]
- 449 (cohort 1), 9.4% [5.1 23.9] (cohort 2), and 5.1% [0.8 17.1] (cohort 3). Positive predictive

- 450 values of the TS POC CC test strip were 63.3% [44.1 94.5], 71.6% [35.4 98.8], and 46.6%
- 451 [13.5 91.2], and negative predictive values 95.1 [79.4 99.9], 92.4% [77.4 97.3], and
- 452 96.4% [84.2 99.9], respectively (S2 Appendix).



#### 453

#### Figure 5. Sensitivity and specificity of the TS POC CC test strip, rT24H-EITB and serum Ag ELISA to detect cysticercosis in three cohorts recruited in three district hospitals in Tanzania.

456 Results of the same cohort are indicated with the same color. The error bars indicate the 95% credible

457 intervals around the mean estimates. Cohort 1: participants with specific neurological signs and

458 symptoms compatible with NCC (epilepsy and/or severe progressive chronic headache); cohort 2:

459 participants with complaints compatible with intestinal worm infections; cohort 3: participants with

460 other symptom(s). TS POC CC: *T. solium* point-of-care test for cysticercosis; rT24H-EITB: recombinant

461 enzyme-linked immunoelectrotransfer blot; serum Ag ELISA: serum antigen enzyme-linked

462 immunosorbent assay.

### 463 **3.4.3 Agreement between cysticercosis tests**

464 Cohen's kappa, positive and negative agreements between each of the different tests are

- shown in Table 3, for each of the three cohorts. The agreement between the TS POC CC
- 466 result and the rT24H-EITB was substantial within cohort 1 ( $\kappa = 66\%$ ), but only fair within

the other cohorts ( $\kappa = 33-38\%$ ). Within each cohort, the agreement of TS POC CC with serum Ag ELISA was lower than the agreement with rT24H-EITB (Table 3). In cohort 1, there was a substantial agreement between the rT24H-EITB and serum Ag ELISA ( $\kappa = 74\%$ ), whereas the agreement between both tests in the other cohorts was low ( $\kappa < 20\%$ ). The negative agreements were all above 94%, but the positive agreements were lower, varying between 11% and 76%.

#### 473 **4 Discussion**

474 The primary objective of this study was to assess the sensitivity and specificity of the TS 475 POC test under field conditions in people attending district hospitals in Tanzania for the detection of taeniosis and cysticercosis. The study lateral-flow test demonstrated a moderate 476 477 sensitivity for cysticercosis detection in individuals suspect of (neuro)cysticercosis. In 478 contrast, the sensitivity was largely unsatisfactory for the detection of taeniosis even in 479 clinical suspects. The relatively high specificity of the test may be useful in clinical care. 480 We used several strategies to minimize bias in this diagnostic accuracy study [10,11]. Despite 481 these efforts, certain factors may have affected the sensitivity and specificity estimates. One 482 potential source of bias for the taeniosis evaluation is the time interval between the initial test 483 and the stool sample collection, which could result in disease progression bias. Although 484 most participants submitted a stool sample within two days of the TS POC test, some waited considerably longer to return a stool sample, raising the possibility of infection acquisition or 485 486 changes in egg excretion during the interval. In contrast, blood samples were collected 487 promptly by a nurse, thus limiting the risk of disease progression bias. Logistical issues, such 488 as sample shipment and COVID-19-related delays, may have further affected test outcomes. 489 Prolonged storage could have led to false negatives and variations in the stability of antibodies, antigens, and DNA, could have contributed to the observed low agreement 490

491 between tests. Our two-stage design, sampling all POC test positives and a subset of 492 negatives, aimed to reduce the number of reference tests. However, due to the lower 493 sensitivity of the TS POC test than the preliminary laboratory tests, we only identified few 494 infections, particularly for taeniosis, which resulted in wide credible intervals for sensitivity. 495 Despite these limitations, this study showed valuable insights in diagnostic tests for T. solium 496 infections in hospital settings. Its main strength was evaluating the test in target populations, 497 yielding more realistic estimates than diagnostic case-control studies conducted in laboratory 498 settings.

499 Rapid diagnostic tests can be particularly useful for identifying *T. solium* taeniosis, as they 500 shorten diagnostic turnaround times and enable guicker treatment, preventing the spread of 501 infectious eggs. A high sensitivity is essential to avoid missing infected individuals. In our 502 study, the TS POC T test strip had a sensitivity of 40% to 50%, with wide credible intervals, 503 falling short of the 95% sensitivity threshold recommended in Target Product Profiles (TPPs) 504 for monitoring of control interventions, as well as for diagnosis and treatment [8]. 505 Additionally, rES33-EITB, copro Ag ELISA and copro mPCR also showed sensitivities 506 below the 95% TPP threshold, highlighting the need for improved diagnostic methods 507 validated under field conditions. The low disease prevalence complicates sensitivity 508 assessment, as seen in our cohorts where true prevalence was very low and similar to 0.6% 509 [28] and 1.8% [12] in rural communities of Eastern Province of Zambia. Achieving a 510 sensitivity above the 95% TPP threshold for taeniosis tests under field conditions with current 511 tests and low prevalence would thus require very large studies to achieve accurate field 512 validation.

513 The sensitivity of the TS POC CC test strip for detecting infection with cysticerci varied 514 across the different cohorts. These differences were expected due to varying disease spectra 515 among populations. Sensitivity was low among participants with gastrointestinal symptoms

516 (25% [6-53%]) and other symptoms (44% [2-95%]), similar to rates observed in 517 asymptomatic rural communities in Zambia (35% [14–63%]) [13]. The sensitivity was higher 518 among participants with neurological signs/symptoms (77% [38-99%]), likely due to higher 519 parasitic loads, resulting in elevated antibody/antigen levels [29], which are more easily 520 detected by a diagnostic test. As such, both rT24H-EITB and serum Ag ELISA also 521 demonstrated higher sensitivities in individuals with neurological signs/symptoms compared 522 to the other cohorts and asymptomatic community members [13]. Consequently, also the 523 agreement between the different cysticercosis tests was higher in individuals with 524 neurological signs/symptoms than in the other cohorts and asymptomatic community 525 members [13]. The almost perfect agreement that has been reported for different NCC tests 526 [30–32] should thus be interpreted cautiously, as it may not be representative for the target 527 population. Differences in test agreement among subgroups stratified by location and stage of 528 the lesions [33] further suggests variability according to disease spectrum. Similarly, the TS 529 POC CC test strip and serological tests showed a sensitivity of 44 to 50% for NCC diagnosis 530 in hospital settings, but above 98% among patients with active lesions [14]. This study shows 531 that agreement between serological tests is only minimal to moderate under field conditions, 532 particularly in individuals not clinically suspect of NCC. 533 There is no gold standard test for diagnosing cysticercosis, and existing tests have been 534 evaluated almost exclusively for neuroimaging-based detection of NCC [29-34], often in 535 (severely diseased) symptomatic patients in diagnostic case-control studies. This leads to an 536 overestimation of the diagnostic performance in laboratory settings [35], making these 537 estimates not representative for the target population. The lack of data on test performance

- 538 for cysticercosis detection made selecting prior information challenging. Priors were updated
- based on community-level evaluation data [13], and were chosen to be minimally restrictive,

540 contributing to wide credible intervals. More knowledge on serological test performance

541 under field conditions is urgently needed, not just for NCC.

542 Compared to the sensitivities, the specificities of all tests were more precisely estimated and generally high, exceeding 90% in all cohorts. When used in a magnetic 543 544 immunochromatographic test, the rES33 antigen had a specificity of 96% using serum from 545 regions without taeniosis/cysticercosis transmission, with some reactivity in patients infected 546 with Echinococcus granulosus, Ascaris lumbricoides, Plasmodium falciparum, Trichinella 547 and *Schistosoma mansoni* [36]. As we evaluated the tests in an endemic region and under 548 field conditions, the specificity estimates that were obtained in our study are likely more 549 realistic than the ones obtained using diagnostic case-control studies. Despite the potential

550 presence of comorbid infections in our study populations, the specificity of the TS POC test

seems rather high, and may be useful for epidemiological studies and monitoring of

interventions. Nevertheless, when the disease prevalence decreases, a very high specificity is

required [37], so the specificity of the tests would have to be evaluated in post-intervention

554 populations to determine if it is fit for purpose.

# 555 **5 Conclusions**

556 The TS POC test demonstrated a moderate sensitivity for infections with cysticerci in individuals with neurological signs/symptoms, but a high specificity, which could be useful 557 for the care of this population. In contrast, the sensitivity was largely unsatisfactory for the 558 559 detection of T. solium taeniosis, even in clinical suspected cases, an infection for which 560 straightforward treatment is available. This study also highlights the lack of knowledge on the 561 performance of the currently used diagnostic tests for *T. solium* taeniosis and cysticercosis under field conditions. Most tests have only been evaluated in laboratory settings using 562 diagnostic case-control studies, resulting in an overestimation of the diagnostic performance 563

564 of the tests. Additionally, transforming a continuous variable, such as antibody levels or DNA 565 concentrations, into a binary outcome (presence or absence of infection) leads to a loss of valuable information, which can result in misclassification and diminish the overall accuracy 566 567 of a diagnostic test. The variability in test performance across different cohorts underscores 568 the importance of estimating the diagnostic accuracy of a test in the intended target 569 population, and that the sensitivity cannot be extrapolated to populations with a different 570 disease spectrum. Since also the reference tests in the current study performed poorly under 571 field conditions, this study showed the overall need to develop more sensitive and specific 572 diagnostic tests to detect human T. solium taeniosis and cysticercosis.

# 573 6 Acknowledgements

574 We extend our gratitude to all the dedicated hospital staff members and the willing participants for their invaluable contributions to this study. Special recognition is also due to 575 the laboratory technicians, Sandra Vangeenberghe, Maxwell Masuku, Chembensofu 576 577 Mwelwa, Anke Van Hul, Ana Lucia Fajardo for their diligent analysis of the samples. 578 Special thanks are due to the members of the SOLID External Advisory Board for their 579 guidance, and Helena Ngowi and Maria V. Johansen for their valuable contributions during 580 the initial phase of this study. This work is dedicated to the memory of our esteemed 581 colleague and friend, Dr. Benedict Ndawi.

582 7 Data availability

583 The data cannot be publicly shared due to ethical and privacy considerations but are

accessible through the Data Access Committee at the Institute of Tropical Medicine,

585 Antwerp. You can find more information and request access via <u>https://www.itg.be/E/data-</u>

586 <u>sharing-open-access</u>, or via email at <u>ITMresearchdataaccess@itg.be</u>.

# 587 8 Funding

- 588 Funding for this research was provided by the European & Developing Countries Clinical
- 589 Trials Partnership (grant number DRIA2014-308) and the German Federal Ministry of
- 590 Education and Research (grant number 01KA1617) as part of the research grant titled
- 591 "Evaluation of an antibody detecting point-of-care test for the diagnosis of *Taenia solium*
- taeniosis and (neuro)cysticercosis in communities and primary care settings of highly
- 593 endemic, resource-poor areas in Tanzania and Zambia, including training of and technology
- 594 transfer to the Regional Reference Laboratory and health centers (SOLID)". The funders of
- this research had no role in this study.

## 596 9 Declaration of interest

- 597 VS, JN and SH were involved in the development of the TS POC test. ITM (Nationalestraat
- 598 155, B-2000 Antwerp, Belgium) is the sponsor of the study. The funders had no role in the
- design of the study, in the collection, analyses, or interpretation of data, in the writing of the
- 600 manuscript, or in the decision to publish the results.

## 601 **10 References**

- Ngowi HA, Winkler AS, Braae UC, Mdegela RH, Mkupasi EM, Kabululu ML, et al. Taenia solium taeniosis and cysticercosis literature in Tanzania provides research evidence justification for control: A systematic scoping review. PLOS ONE. 2019;14: e0217420. doi:10.1371/journal.pone.0217420
- Zulu G, Stelzle D, Mwape KE, Welte TM, Strømme H, Mubanga C, et al. The
  epidemiology of human Taenia solium infections: A systematic review of the
  distribution in Eastern and Southern Africa. PLoS Negl Trop Dis. 2023;17: e0011042.
  doi:10.1371/journal.pntd.0011042
- Trevisan C, Devleesschauwer B, Schmidt V, Winkler AS, Harrison W, Johansen MV.
  The societal cost of Taenia solium cysticercosis in Tanzania. Acta Trop. 2017;165: 141–
  154. doi:10.1016/j.actatropica.2015.12.021

- 613 4. Gómez-Morales MA, Gárate T, Blocher J, Devleesschauwer B, Smit GSA, Schmidt V,
  614 et al. Present status of laboratory diagnosis of human taeniosis/cysticercosis in Europe.
  615 Eur J Clin Microbiol Infect Dis. 2017;36: 2029–2040. doi:10.1007/s10096-017-3029-1
- 616 5. Rodriguez S, Wilkins P, Dorny P. Immunological and molecular diagnosis of
  617 cysticercosis. Pathog Glob Health. 2012;106: 286–298.
  618 doi:10.1179/2047773212Y.0000000048
- 6. Mwape KE, Gabriël S. The Parasitological, Immunological, and Molecular Diagnosis of
  Human Taeniasis with Special Emphasis on Taenia solium Taeniasis. Curr Trop Med
  Rep. 2014;1: 173–180. doi:10.1007/s40475-014-0028-5
- Yamasaki H, Allan JC, Sato MO, Nakao M, Sako Y, Nakaya K, et al. DNA differential
  diagnosis of taeniasis and cysticercosis by multiplex PCR. J Clin Microbiol. 2004;42:
  548–553. doi:10.1128/JCM.42.2.548-553.2004
- 8. Donadeu M, Fahrion AS, Olliaro PL, Abela-Ridder B. Target product profiles for the
  diagnosis of Taenia solium taeniasis, neurocysticercosis and porcine cysticercosis. PLoS
  Negl Trop Dis. 2017;11: e0005875. doi:10.1371/journal.pntd.0005875
- Mubanga C, Mwape KE, Phiri IK, Trevisan C, Zulu G, Chabala C, et al. Progress on the
  development of rapid diagnostic tests for foodborne neglected zoonotic helminthiases: A
  systematic review. Acta Trop. 2019;194: 135–147.
  doi:10.1016/j.actatropica.2019.03.030
- 10. Van Damme I, Trevisan C, Mwape KE, Schmidt V, Magnussen P, Zulu G, et al. Trial
  Design for a Diagnostic Accuracy Study of a Point-of-Care Test for the Detection of
  Taenia solium Taeniosis and (Neuro)Cysticercosis in Community Settings of Highly
  Endemic, Resource-Poor Areas in Zambia: Challenges and Rationale. Diagnostics.
  2021;11: 1138. doi:10.3390/diagnostics11071138
- 11. Trevisan C, Van Damme I, Ngowi B, Schmidt V, Stelzle D, Møller KS, et al. Trial
  Design of a Prospective Multicenter Diagnostic Accuracy Study of a Point-of-Care Test
  for the Detection of Taenia solium Taeniosis and Neurocysticercosis in Hospital-Based
  Settings in Tanzania. Diagnostics. 2021;11: 1528. doi:10.3390/diagnostics11091528
- Mubanga C, Trevisan C, Van Damme I, Schmidt V, Phiri IK, Zulu G, et al. Challenges
  Encountered When Evaluating an Antibody-Detecting Point-of-Care Test for Taeniosis
  in an Endemic Community in Zambia: A Prospective Diagnostic Accuracy Study.
  Diagnostics. 2021;11: 2039. doi:10.3390/diagnostics11112039
- Mubanga C, Van Damme I, Trevisan C, Schmidt V, Phiri IK, Zulu G, et al. Evaluation
  of an Antibody Detecting Point of Care Test for Diagnosis of Taenia solium
  Cysticercosis in a Zambian Rural Community: A Prospective Diagnostic Accuracy
  Study. Diagnostics. 2021;11: 2121. doi:10.3390/diagnostics11112121
- 649 14. Stelzle D, Makasi CE, Schmidt V, Van Damme I, Trevisan C, Ruether C, et al.
  650 Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis
  651 in rural southern Tanzania: a diagnostic accuracy study. Lancet Infect Dis. 2024;24: 98–
  652 106. doi:10.1016/S1473-3099(23)00378-X

653 15. Zulu G, Stelzle D, Mwape KE, Van Damme I, Trevisan C, Mubanga C, et al. The 654 Performance of a Point-of-Care Test for the Diagnosis of Neurocysticercosis in a 655 Resource-Poor Community Setting in Zambia – a Diagnostic Accuracy Study. 656 Rochester, NY; 2024. doi:10.2139/ssrn.4746924 16. Stelzle D, Makasi C, Schmidt V, Trevisan C, Van Damme I, Welte TM, et al. 657 Epidemiological, clinical and radiological characteristics of people with 658 659 neurocysticercosis in Tanzania-A cross-sectional study. PLoS Negl Trop Dis. 2022;16: 660 e0010911. doi:10.1371/journal.pntd.0010911 661 17. Noh J, Rodriguez S, Lee Y-M, Handali S, Gonzalez AE, Gilman RH, et al. 662 Recombinant Protein- and Synthetic Peptide-Based Immunoblot Test for Diagnosis of Neurocysticercosis. J Clin Microbiol. 2014;52: 1429-1434. doi:10.1128/JCM.03260-13 663 664 18. Levine MZ, Calderón S JC, Wilkins PP, Lane WS, Asara JM, Hancock K, et al. Characterization, cloningn and expression of two diagnostic antigens for Taenia solium 665 666 tapeworm infection. J Parasitol. 2004;90: 631-638. doi:10.1645/GE-189R 19. Mubanga C, Mwape KE, Phiri IK, Trevisan C, Kabululu M, Zulu G, et al. Operational 667 668 characteristics of an antibody detecting point of care test for Taenia solium infections in 669 a community and hospital setting. BMC Infect Dis. 2021;21: 607. doi:10.1186/s12879-670 021-06320-3 671 20. Allan JC, Avila G, Noval JG, Flisser A, Craig PS. Immunodiagnosis of taeniasis by 672 coproantigen detection. Parasitology. 1990;101: 473–477. 673 doi:10.1017/S0031182000060686 674 21. Mwape KE, Phiri IK, Praet N, Muma JB, Zulu G, Bossche PV den, et al. Taenia solium 675 Infections in a Rural Area of Eastern Zambia-A Community Based Study, PLoS Negl 676 Trop Dis. 2012;6: e1594. doi:10.1371/journal.pntd.0001594 22. Levine MZ, Lewis MM, Rodriguez S, Jimenez JA, Khan A, Lin S, et al. Development 677 678 of an enzyme-linked immunoelectrotransfer blot (EITB) assay using two Baculovirus 679 expressed recombinant antigens for diagnosis of Taenia solium taeniasis. J Parasitol. 2007;93: 409-417. doi:10.1645/GE-938R.1 680 681 Dorny P, Phiri IK, Vercruysse J, Gabriel S, Willingham AL, Brandt J, et al. A Bayesian 23. approach for estimating values for prevalence and diagnostic test characteristics of 682 683 porcine cysticercosis. Int J Parasitol. 2004;34: 569-576. 684 doi:10.1016/j.ijpara.2003.11.014 685 24. Berkvens D, Speybroeck N, Praet N, Adel A, Lesaffre E. Estimating disease prevalence in a Bayesian framework using probabilistic constraints. Epidemiology. 2006;17: 145-686 687 153. doi:10.1097/01.ede.0000198422.64801.8d 688 25. Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, et al. 689 STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. Prev Vet Med. 2017;138: 37-47. 690 691 doi:10.1016/j.prevetmed.2017.01.006

- 692 26. Cicchetti DV, Feinstein AR. High agreement but low kappa: II. Resolving the
  693 paradoxes. J Clin Epidemiol. 1990;43: 551–558. doi:10.1016/0895-4356(90)90159-M
- R Core Team. R: A language and environment for statistical computing. Vienna,
  Austria: R foundation for statistical computing; 2023. Available: https://www.R-project.org/
- Praet N, Verweij JJ, Mwape KE, Phiri IK, Muma JB, Zulu G, et al. Bayesian modelling
  to estimate the test characteristics of coprology, coproantigen ELISA and a novel realtime PCR for the diagnosis of taeniasis. Trop Med Int Health. 2013;18: 608–614.
  doi:10.1111/tmi.12089
- Zea-Vera A, Cordova EG, Rodriguez S, Gonzales I, Pretell EJ, Castillo Y, et al. Parasite
  Antigen in Serum Predicts the Presence of Viable Brain Parasites in Patients With
  Apparently Calcified Cysticercosis Only. Clin Infect Dis. 2013;57: e154–e159.
  doi:10.1093/cid/cit422
- 30. Corda M, Sciurba J, Blaha J, Mahanty S, Paredes A, Garcia HH, et al. A recombinant monoclonal-based Taenia antigen assay that reflects disease activity in extraparenchymal neurocysticercosis. PLoS Negl Trop Dis. 2022;16: e0010442. doi:10.1371/journal.pntd.0010442
- 31. Dermauw V, Carabin H, Cissé A, Millogo A, Tarnagda Z, Ganaba R, et al. Evaluating
  the Recombinant T24H Enzyme-Linked Immunoelectrotransfer Blot Assay for the
  Diagnosis of Neurocysticercosis in a Panel of Samples from a Large Community-Based
  Randomized Control Trial in 60 Villages in Burkina Faso. Am J Trop Med Hyg.
  2017;98: 565–569. doi:10.4269/ajtmh.17-0541
- Morillo M, Noguera C, Gallego L, Fernández Z, Mata M, Khattar S, et al.
  Characterization and evaluation of three new recombinant antigens of Taenia solium for
  the immunodiagnosis of cysticercosis. Mol Biochem Parasitol. 2020;240: 111321.
  doi:10.1016/j.molbiopara.2020.111321
- 33. Castillo Y, Toribio LM, Guzman C, Arroyo G, Espinoza C, Saavedra H, et al.
  Consistent Measurement of Parasite-Specific Antigen Levels in Sera of Patients with
  Neurocysticercosis Using Two Different Monoclonal Antibody (mAb)-Based EnzymeLinked Immunosorbent Assays. Pathogens. 2023;12: 566.
  doi:10.3390/pathogens12040566
- 34. Gabriël S, Blocher J, Dorny P, Abatih EN, Schmutzhard E, Ombay M, et al. Added
  value of antigen ELISA in the diagnosis of neurocysticercosis in resource poor settings.
  PLoS Negl Trop Dis. 2012;6: e1851. doi:10.1371/journal.pntd.0001851
- Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case–Control and Two-Gate Designs in Diagnostic Accuracy Studies. Clin Chem. 2005;51: 1335–1341. doi:10.1373/clinchem.2005.048595
- 36. Handali S, Klarman M, Gaspard AN, Dong XF, LaBorde R, Noh J, et al. Development
  and Evaluation of a Magnetic Immunochromatographic Test To Detect Taenia solium,

- Which Causes Taeniasis and Neurocysticercosis in Humans. Clin Vaccine Immunol
  CVI. 2010;17: 631–637. doi:10.1128/CVI.00511-09
- Gass K. Time for a diagnostic sea-change: Rethinking neglected tropical disease
  diagnostics to achieve elimination. PLoS Negl Trop Dis. 2020;14: e0008933.
  doi:10.1371/journal.pntd.0008933

736

# 738 Supporting information Captions

- 739 S1 Appendix. Patient recruitment. Table 1A Recruitment of cohort 1 participants from the
- outpatient department and mental health clinic. Table 1B. Symptoms of participants in cohort
- 1 during recruitment. The results are from screening questionnaires administered by local
- 742 nurses.
- 743 S2 Appendix. Output of Bayesian analyses.

# Excluded (n=141)

- Reason for recruitment unclear (n=3)
- Incorrect headache criteria used (n=138)

# No reference test results

- Not selected (n = 462)
- No serum sample (n=4)
- No stool sample (n=4)
- No reference test results
- No serum sample (n=9)
- No stool sample (n=9)



# No reference test results

- Not selected (n = 1497)
- No serum sample (n=29)
- No stool sample (n=26)

# No reference test results

- No serum sample (n=11)
- No stool sample (n=11)

# No reference test results

- No serum sample (n=2)
- No stool sample (n=2)

# Excluded (n = 1)

- Symptoms not clear (n = 1)

# No reference test results

- Not selected (n = 594)
- No serum sample (n=10)
- No stool sample (n=11)

No reference test results

- No serum sample (n=3)
- No stool sample (n=1)